pentobarbital will decrease the extent or impact of elbasvir/grazoprevir by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. The therapeutic influence of elbasvir/grazoprevir may be decreased if coadministered with powerful CYP3A inducers and it is consequently contraindicated.pentobarbital will lessen the extent or impact